| Date Filed | Type | Description |
| 10/03/2017 |
8-K
| Quarterly results |
| 09/25/2017 |
8-K
| Quarterly results |
| 09/05/2017 |
8-K
| Quarterly results |
| 08/28/2017 |
8-K
| Quarterly results |
| 08/08/2017 |
8-K
| Quarterly results |
| 06/23/2017 |
8-K
| Form 8-K - Current report |
| 05/08/2017 |
8-K
| Form 8-K - Current report |
| 04/12/2017 |
8-K
| Form 8-K - Current report |
| 03/16/2017 |
8-K
| Form 8-K - Current report |
| 03/06/2017 |
8-K
| Form 8-K - Current report |
| 02/28/2017 |
8-K
| Form 8-K - Current report |
| 01/10/2017 |
8-K
| Form 8-K - Current report |
| 01/09/2017 |
8-K
| Form 8-K - Current report |
| 01/05/2017 |
8-K
| Form 8-K - Current report |
| 12/27/2016 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 09/26/2016 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/08/2016 |
8-K
| Form 8-K - Current report |
| 07/06/2016 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 06/06/2016 |
8-K
| Form 8-K - Current report |
| 06/02/2016 |
8-K
| Form 8-K - Current report |
| 05/16/2016 |
8-K
| Form 8-K - Current report |
| 05/09/2016 |
8-K
| Quarterly results |
| 02/29/2016 |
8-K
| Quarterly results |
| 12/22/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/10/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/08/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/07/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/12/2015 |
8-K
| Quarterly results|
Docs:
|
"Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update Santa Monica, Calif., November 12, 2015 - Kite Pharma, Inc. , a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today reported financial results for the quarter ended September 30, 2015. “Over the past few months, we have achieved many significant corporate and clinical development milestones, including the initiation of two pivotal Phase 2 studies of our lead product candidate, KTE-C19,” noted Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer. “Our ZUMA-1 trial is enrolling patients with aggressive, refractory non-Hodgkin's lymphoma, while our ZUMA-2 trial is enrolling patients with relap..." |
|
| 11/05/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
| 10/27/2015 |
8-K
| Entry into a Material Definitive Agreement |
| 10/20/2015 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor -Based Products to Treat Tumors Expressing MAGE SANTA MONICA, Calif., Oct. 20, 2015 — Kite Pharma, Inc. , a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health for intellectual property related to T Cell Receptor -based product candidates directed against MAGE A3 and A3/A6 antigens for the treatment of tumors expressing MAGE, which include lung, pancreatic, gastric, and breast cancers, among others. The National Cancer Institute , with Dr. Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery..." |
|
| 09/15/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/17/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
|